AAIC 2025 Abstract
Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries
Study in peoplePopulations
Abstract
Background: Lecanemab for treating early Alzheimer's disease has been available in the United States since January 2023.
